Sulforaphane: Benefits, Evidence, and What Broccoli Sprouts Can Actually Do

A compound from broccoli sprouts is one of the most studied plant chemicals for inflammation and cellular defense. Here is what the research actually supports.

Track the foods that fit your goals. Track it free with Ration →

By the Ration Editorial Team · Reviewed against primary research · Updated July 14, 2026

Sulforaphane is a compound that belongs to a class of plant chemicals called isothiocyanates.

It does not exist ready-made in the plant. Broccoli and other cruciferous vegetables store a precursor called glucoraphanin.

When you chew, chop, or crush the vegetable, an enzyme called myrosinase is released and converts glucoraphanin into sulforaphane. Cooking can destroy myrosinase, which is why raw or lightly steamed preparations tend to yield more active compound.

• Broccoli sprouts (by far the most concentrated source)
• Mature broccoli
• Brussels sprouts
• Cabbage
• Kale
• Cauliflower
• Mustard greens

Sulforaphane's best known mechanism involves a cellular pathway called Nrf2, short for nuclear factor erythroid 2-related factor 2.

Nrf2 acts like a master switch for the body's own antioxidant defenses. Normally it is held inactive by a protein called Keap1.

Sulforaphane interferes with Keap1, freeing Nrf2 to move into the cell nucleus and switch on genes that produce antioxidant and detoxifying enzymes^[3][6][8].

Separately, sulforaphane appears to dampen NF-kB, a pathway that drives inflammation, which may explain its effects on inflammatory markers like C-reactive protein^[3][9].

This is where the human evidence is strongest. Several small trials have measured C-reactive protein, or CRP, a blood marker that rises with inflammation.

A randomized trial in overweight adults found that long-term consumption of broccoli sprouts reduced inflammatory markers, including CRP, compared with controls^[7].

In people with HIV on suppressive antiretroviral therapy, sulforaphane supplementation was studied for its effects on inflammation and metabolic markers, with signals suggesting a benefit on inflammatory status^[4].

A 2025 study looking at patients recovering from subarachnoid hemorrhage found associations between CRP levels and fatigue, underscoring why researchers care about bringing CRP down in the first place^[1].

Animal work backs this up mechanistically. In rats with acetaminophen-induced liver injury, sulforaphane reduced markers of oxidative stress and inflammation^[9]. In hypercholesterolemic rabbits, it improved endothelial function and slowed atherosclerosis development, both processes tied to vascular inflammation^[10].

Taken together, this is a reasonably consistent signal across species and study types, which is why the evidence grade for CRP reduction is comparatively strong.

• ↓C-Reactive ProteinAHuman trials

  Research may lower C-Reactive Protein · strong agreement · 6 studies

  View 5 studies on PubMed

  • Effects of long-term consumption of broccoli sprouts on inflammatory markers in overweight subjects (2019)
  • C-reactive protein and fatigue after subarachnoid haemorrhage (2025)
  • The effect of sulforaphane on oxidative stress and inflammation in rats with toxic hepatitis induced by acetaminophene (2017)
  • Sulforaphane attenuates the development of atherosclerosis and improves endothelial dysfunction in hypercholesterolemic rabbits (2016)
  • Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model (2025)
• ↑Nrf2 Antioxidant PathwayDPreliminary

  Research may raise Nrf2 Antioxidant Pathway · strong agreement · 6 studies

  View 5 studies on PubMed

  • Eat Your Broccoli: Oxidative Stress, NRF2, and Sulforaphane in Chronic Kidney Disease (2021)
  • Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders (2020)
  • Sulforaphane and Other Nutrigenomic Nrf2 Activators: Can the Clinician's Expectation Be Matched by the Reality? (2016)
  • Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment (2018)
  • Exploring sulforaphane as neurotherapeutic: targeting Nrf2-Keap & Nf-Kb pathway crosstalk in ASD (2024)

The database above summarizes the two most graded effects. Notice the gap between them.

CRP reduction carries a grade of A, built from six sources including human trials. Nrf2 activation, despite being sulforaphane's signature mechanism and the subject of dozens of papers, carries a grade of D.

That is not a contradiction. Nrf2 activation is extremely well proven in cell cultures and animal models^[6][8][12], but reviewers have pointed out that translating this into a measurable, reliable human outcome has been harder than the hype suggests^[11].

In other words, we know sulforaphane reliably flips the Nrf2 switch in a dish or a rodent. We have much less confidence about what that switch-flipping reliably does for a person's health markers.

Researchers have explored sulforaphane across a wide range of conditions, largely because oxidative stress and inflammation show up in so many diseases.

• Cancer, where sulforaphane is studied as a chemopreventive and adjunct compound, including in nanoparticle delivery systems aimed at improving tumor targeting^[2][8][12]
• Chronic kidney disease, where impaired Nrf2 signaling is thought to contribute to oxidative damage^[5]
• Autism spectrum disorder and other neurological conditions, where Nrf2-NF-kB crosstalk has been proposed as a target^[3][6]
• Cardiovascular health, based on animal data showing improved endothelial function^[10]
• People with HIV on antiretroviral therapy, where chronic low-grade inflammation is common^[4]
• General metabolic and inflammatory health in overweight adults^[7]

None of this means sulforaphane is an established treatment for these conditions. Most of the mechanistic work is preclinical, and human trials remain small and early stage.

There is no established, agreed-upon dose of sulforaphane for any specific health outcome. Trials have used varying amounts, often delivered as broccoli sprout extracts or sprout powders standardized to glucoraphanin content.

• Fresh broccoli sprouts, eaten raw or added to food after cooking is done
• Broccoli sprout extract capsules or powders, standardized for glucoraphanin
• Myrosinase-added supplements, meant to improve conversion to active sulforaphane
• Experimental delivery systems like nanoliposomes, so far tested mainly in animal models^[2]

Because myrosinase is heat sensitive, some supplement makers pair glucoraphanin powder with a separate myrosinase source, often from mustard seed, to boost conversion after the product is made.

Broccoli sprouts and other cruciferous vegetables have a long history of safe consumption as food, and sulforaphane derived from them is generally considered well tolerated in the doses used in trials.

• Mild gastrointestinal upset has been reported with concentrated extracts
• Cruciferous vegetables, including broccoli sprouts, can interact with thyroid function in very high amounts due to their goitrogen content
• Supplement forms are not standardized across brands, so actual sulforaphane content can vary widely
• Long-term safety data on high-dose extracts in humans is still limited

As with any concentrated plant extract, this is not medical advice, and anyone with a health condition or on medication should discuss supplements with a clinician before starting one.

Sulforaphane has one of the more interesting evidence profiles among plant compounds. Its anti-inflammatory effect, measured through CRP, has decent human trial support^[7][4][1].

Its headline mechanism, activating Nrf2, is scientifically fascinating and extensively documented in labs, but has not yet been proven to reliably change human health outcomes^[11].

Eating broccoli sprouts remains a reasonable way to get sulforaphane through food, with a strong safety track record, while researchers continue working out what its cellular effects actually translate to in people.